Management Team

Tim Wilson
Tim Wilson
Chief Executive Officer
Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.
Vivienne Cox
Vivienne Cox
Chief Operating Officer
Vivienne’s career in the biotech industry includes research management roles at Wellcome Biotech and SmithKline Beecham. She was co-founder of Adprotech Ltd, a company developing novel proteins therapeutics and vaccines. In 2001 she founded UK Bioscience Consultants and has provided life science commercialization consultancy to many of the UK’s leading universities and medical institutes. She holds a PhD from Imperial College, London.
Kevin FitzGerald
Kevin FitzGerald
Chief Scientific Officer
Kevin began his career in the biotechnology industry at Cambridge Antibody Technology (now part of Medimmune, an AstraZeneca company) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the laboratory of Sir Gregory Winter at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London.
Phil Boyd
Phil Boyd
Chief Financial Officer
Phil is a qualified management accountant and currently acts as CFO for private life science companies Enterprise Therapeutics Ltd and Caldan Therapeutics Ltd. He was CFO of Syntaxin Ltd from 2007 through to its acquisition by Ipsen in 2013, CFO of Tiziana Lifesciences plc from 2014 to 2015, taking it through its IPO in April 2014, and CFO of Oxford BioDynamics plc from 2015 to 2016 in preparation for its IPO in December 2016. Previously he was UK Finance Director of Evotec and Cambridge Discovery Chemistry, and a management consultant with PwC. He has a BSc in Biotechnology and a PhD in Genetics from Leeds University.